Journal Article

Rifaximin: A Novel Nonabsorbed Rifamycin for Gastrointestinal Disorders

Javier A. Adachi and Herbert L. DuPont

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 42, issue 4, pages 541-547
Published in print February 2006 | ISSN: 1058-4838
Published online February 2006 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/499950
Rifaximin: A Novel Nonabsorbed Rifamycin for Gastrointestinal Disorders

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Rifaximin, a virtually nonabsorbed (<0.4%) rifamycin drug, has in vitro activity against aerobic and anaerobic gram-positive and gram-negative microorganisms. Because rifaximin is nonabsorbed, systemic adverse effects are unusual, and after 3 days of therapy, the fecal level of the drug reaches 8000 µg/g. Moreover, the important selection of resistant mutants by the related drug, rifampin, has not yet been observed for rifaximin. Rifaximin has been demonstrated to reduce the duration of traveler's diarrhea secondary to noninvasive bacterial pathogens and recently has been shown to reduce the occurrence of the disease when used for chemoprophylaxis. Preliminary studies have demonstrated its potential for the treatment of other gastrointestinal disorders, such as hepatic encephalopathy. Additional studies should be performed to further define the role of rifaximin in the treatment of gastrointestinal diseases in adults and children.

Journal Article.  5146 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.